Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | adenosine A1 receptor | Starlite/ChEMBL | References |
Homo sapiens | adenosine A3 receptor | Starlite/ChEMBL | References |
Homo sapiens | adenosine A2b receptor | Starlite/ChEMBL | References |
Homo sapiens | adenosine A2a receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | hypothetical protein | adenosine A1 receptor | 326 aa | 305 aa | 21.0 % |
Brugia malayi | follicle stimulating hormone receptor | adenosine A2a receptor | 412 aa | 336 aa | 22.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.0488 | 1 | 1 |
Echinococcus granulosus | nmda type glutamate receptor | 0.027 | 0.4245 | 0.3336 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0488 | 1 | 1 |
Leishmania major | 0.0488 | 1 | 0.5 | |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0488 | 1 | 1 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.027 | 0.4245 | 0.4245 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.0488 | 1 | 1 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.0488 | 1 | 0.5 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0488 | 1 | 1 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.0488 | 1 | 1 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0177 | 0.1779 | 0.048 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0177 | 0.1779 | 0.1779 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.0161 | 0.1365 | 0.1365 |
Toxoplasma gondii | fructose-bisphospatase II | 0.0488 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 26 % | Antagonist activity at human adenosine A2B receptor expressed in CHO cells asssessed as inhibition of NECA-stimulated cAMP accumulation at 10 uM | ChEMBL. | 17927167 |
Activity (functional) | = 26 % | Antagonist activity at human adenosine A2B receptor expressed in CHO cells asssessed as inhibition of NECA-stimulated cAMP accumulation at 10 uM | ChEMBL. | 17927167 |
IC50 (functional) | = 11.61 nM | Antagonist activity at human adenosine A3 receptor expressed in CHO cells asssessed as inhibition of forskolin-stimulated cAMP accumulation | ChEMBL. | 17927167 |
IC50 (functional) | = 11.61 nM | Antagonist activity at human adenosine A3 receptor expressed in CHO cells asssessed as inhibition of forskolin-stimulated cAMP accumulation | ChEMBL. | 17927167 |
IC50 (functional) | > 1000 nM | Antagonist activity at human adenosine A2B receptor expressed in CHO cells asssessed as inhibition of NECA-stimulated cAMP accumulation | ChEMBL. | 17927167 |
IC50 (functional) | > 1000 nM | Antagonist activity at human adenosine A2B receptor expressed in CHO cells asssessed as inhibition of NECA-stimulated cAMP accumulation | ChEMBL. | 17927167 |
Ki (binding) | = 12.3 nM | Displacement of [3H]AB-MECA from human adenosine A3 receptor expressed in CHO cells | ChEMBL. | 17927167 |
Ki (binding) | = 12.3 nM | Displacement of [3H]AB-MECA from human adenosine A3 receptor expressed in CHO cells | ChEMBL. | 17927167 |
Ki (binding) | > 10000 nM | Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells | ChEMBL. | 17927167 |
Ki (binding) | > 10000 nM | Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells | ChEMBL. | 17927167 |
Ki (binding) | > 10000 nM | Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells | ChEMBL. | 17927167 |
Ki (binding) | > 10000 nM | Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells | ChEMBL. | 17927167 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.